The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification

Not Applicable

• Conditions: Coronary Artery Disease

• Registration Number: NCT01002157
• Lead Sponsor: Maastricht University Medical Center

Brief Summary

Both Coronary Artery Calcification (CAC)and its annual progression are a strong predictors of cardiovascular events. The development of arterial calcification results from imbalance between calcification promoting and inhibiting factors. An important inhibitor of calcification is Matrix Gla Protein (MGP): a protein present in the vascular wall where it is synthesized by Vascular Smooth Muscle Cells (VSMC). MGP requires Vitamin K-mediated carboxylation to function properly. Deficiency of Vitamin K has been demonstrated to cause arterial calcification and a diet containing large amounts of Vitamin K2 was associated with lower CAC and cardiovascular risk. In animal studies, active supplementation of Vitamin K2 caused regression of existing arterial calcification. Therefore, the aim of this randomized, double-blind, placebo-controlled clinical trial is to investigate whether daily supplementation of Vitamin K2 (Menaquinone-7) to patients with established CAC will lead to a decreased progression-rate of CAC after 24 months of follow-up in comparison to placebo.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-10-26
• Study First Submitted QC: 2009-10-26
• Study First Posted: 2009-10-27
• Study Start: 2011-10
• Status Verified: 2018-09
• Last Update Submitted: 2018-09-12
• Last Update Posted: 2018-09-13
• Primary Completion: 2019-10
• Study Completion: 2019-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Age 18 years or older
• Baseline Coronary Computed Tomographic Angiography (CCTA) of sufficient quality
• Baseline Agatston calciumscore 100 - 400

Exclusion Criteria

• Baseline-scan of insufficient quality
• Heart rate greater than 70 beats per minute during first scan.(despite adequate treatment with metoprolol)
• Chronic or paroxysmal Atrial Fibrillation
• Presence or scheduled coronary revascularization procedure
• History of myocardial infarction or stroke.
• Presence of Diabetes Mellitus.
• Known kidney disease or a Glomerular Filtration Rate (GFR)MDRD < 60 ml/min/1.73m2
• Malignant disease (exception: treated basal-cell or squamous cell carcinoma).
• Use of Vitamin K antagonists.
• A life-expectancy < 2 years
• Pregnancy or wish to become pregnant in the near future.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Coronary Artery Calcification-score progression	12 and 24 months

Secondary Outcome Measures

Name	Time	Method
Arterial Stiffness measured by Carotid-Femoral Pulse-Wave Velocity	0, 12 and 24 months
Carotid Intima Media Thickness	0, 12 and 24 months

Trial Locations

Locations (1)

Maastricht University Medical Center; 🇳🇱 Maastricht, Netherlands